We therefore propose (i) to exhaustively describe the spectrum of ATRX alterations in a large cohort of 591 gliomas from the TCGA, in relation to published data on TMM, and (ii) to functionally assess the ALT process in a cohort of 100 gliomas, correlating findings with standard clinical diagnostic criteria (NGS, IHC). The gene discussed is GPT; the disease is central nervous system cancer.